Degenerative Disc Disease Treatment Market Expected to Reach $46.2 Billion by 2032

According to a new report published by Allied Market Research, titled, “Degenerative Disc Disease Treatment Market," The degenerative disc disease treatment market size was valued at $28 billion in 2022, and is estimated to reach $46.2 billion by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Degenerative Disc Disease (DDD) refers to a condition in which the intervertebral discs in the spine deteriorate or break down over time. These discs act as cushions between the vertebrae, providing flexibility and shock absorption to the spine. When they degenerate, it can lead to pain, instability, and other symptoms. Treatment for degenerative disc disease aims to alleviate symptoms, improve function, and prevent further degeneration.

Continuous advancements in medical technology, including minimally invasive surgical techniques, artificial disc replacements, and biological therapies, enhance treatment options and outcomes for DDD patients. Modern sedentary lifestyles, characterized by prolonged sitting and lack of physical activity, contribute to the development of DDD. The rise in sedentary lifestyle among individuals of all ages increases the incidence of DDD, thereby fueling the demand for treatment.

Growing awareness about spine health and available treatment options through educational campaigns and initiatives encourages individuals to seek medical help for DDD symptoms. Patients are becoming more proactive in managing their spinal health, leading to higher demand for treatment. All these factors are anticipated to drive the degenerative disc disease treatment market Size.

Patients with degenerative disc disease employ a variety of treatments to relieve lower back discomfort. Radiofrequency Ablation (RFA), open surgery, and neurostimulation system implants are among the methods that patients commonly use to relieve pain. For example, according to an Oxford University Press article published in 2021, radiofrequency ablation reduced average pain intensity by around 50% in subjects with chronic low back pain, and the majority of them experienced clinically significant improvements in functional outcomes such as pain intensity, disability, and pain interference.

Continued advancements in medical technology offer opportunities for the development of novel treatment modalities and devices. Innovations in minimally invasive surgical techniques, such as artificial disc replacement and motion-preserving technologies, can improve patient outcomes and reduce recovery times, thereby expanding the market. The exploration of biological therapies, including stem cell treatments and tissue engineering, holds promise for regenerating damaged intervertebral discs.

The development of effective biological treatments could revolutionize DDD management and create significant market opportunities. Emerging economies with aging populations and increasing healthcare spending present untapped market opportunities for DDD treatment providers. Expanding access to advanced treatment options in these regions can drive degenerative disc disease treatment market share and improve patient outcomes on a global scale.

The degenerative disc disease treatment industry is segmented on the basis of drugs, treatment type, end use, route of administration, and region. By drugs, the market is sub-segmented into acetaminophen, NSAIDS (non-steroidal anti-inflammatory drugs), muscle relaxants, and steroids. By treatment type, the market is classified into occupational therapy, physical therapy, special exercises, medications, and weights loss surgery. By end use, the market is classified into hospitals, clinics, and others. By route of administration, the market is classified into oral, and injectable. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in the degenerative disc disease treatment market analysis report include Medtronic plc, Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, Abbott Laboratories, Pfizer Inc., Novartis AG, AstraZeneca plc, Merck & Co., Inc., and Eli Lilly and Company.

The report offers a comprehensive analysis of the global degenerative disc disease treatment market trends by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market. The report also highlights on the present scenario and upcoming trends & developments that are contributing toward the growth of the market. Moreover, restraints and challenges that hold power to obstruct the market growth are also profiled in the report along with the Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the degenerative disc disease treatment industry.

Key Findings of the Study

• Based on drugs, the NSAIDs (non-steroidal anti-inflammatory drugs) sub-segment emerged as the global leader in 2022 and is anticipated to be the fastest growing sub-segment during the degenerative disc disease treatment market forecast period.
• Based on treatment type, the physical therapy sub-segment emerged as the global leader in 2022 and is predicted to show the fastest growth in the upcoming years.
• Based on end use, the hospitals sub-segment emerged as the global leader in 2022 and is predicted to show the fastest growth in the upcoming years.
• Based on route of administration, the oral sub-segment emerged as the global leader in 2022 and is predicted to show the fastest growth in the upcoming years.
• Based on region, the North America market registered the highest degenerative disc disease treatment market share in 2022 and is projected to maintain its position during the forecast period.